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BRIEF REPORTS 
Initial REM Sleep Suppression by Clomipramine: A
Prognostic Tool for Treatment Response in Patients 
with a Major Depressive Disorder 
Dominique Hkhli, Dieter Riemann, Jiirgen Zulley , and 
Mathias Berger 
Kupfer et al. (1976, 1981) demonstrated, in a 
sample of 82 depressed patients, that the amount 
of rapid eye movement (REM) sleep suppres- 
sion during the initial 2 nights of treatment with 
amitriptyline correlated positively with clinical 
response. Gillin et al. (1978) were able to rep- 
licate this finding in six depressed patients. From 
these results, it may be speculated that poly- 
somnographic measurement of REM sleep in 
patients during the initial nights of treatment 
with ~tidepressive drugs may offer the possi- 
bility of improving drug therapy. Whereas in 
clinical practice the response to antidepressive 
medication can only be evaluated after at least 
10-14 days of medication (Woggon 1983), the 
predictive value of REM sleep changes may al- 
low us to avoid unsuccessful treatment early in 
the course of therapy. The above-cited studies 
raise the question of whether or not it is possible 
to establish the threshold of initial REM sleep 
suppression ecessary for successful drug ther- 
apy, thereby providing a substantial differen- 
tiai-therapeutic tool that could influence the 
choice of drug or dosage. The aim of the present 
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study was to test this hy~~esis with clomipra- 
mine, which is characterized as producing the 
most profound suppression of REM sleep (Chen 
1979). 
Methods 
Ten inpatients (7 women, 3 men) with a major 
depressive disorder, endogenous ubtype, ac- 
cording to Research Diagnostic Criteria (RDC) 
(Spitzer et al. 1977) (3 bipolar and 7 unipolar), 
who ranged in age from 18 to 59 years (mean 
40.2 t 15.4 years) and had a 21-item Hamilton 
score ranging from 21 to 36 points (mean 
28.2 rt 5.2) were included in the study. Psy- 
chotic patients and patients with a severe sui- 
cidal risk were excluded. All patients were drug 
free for at least 3 weeks. Sleep was recorded 
polysomnographically on one baseline night, 
preceded by two adaptation nights. Further sleep 
recordings were made during the nights 1 and 
19 of medication. Sleep recordings were scored 
visually according to standardized criteria (Re- 
chtschaffen and Kales 1968). Additionally, re- 
cordings were videotaped for later automated 
analysis, which has not yet been undertaken. 
On the first day of medication, at 4:00 PM, pa- 
tients received 75 mg of clomip~ine. From 
the second day on, patients were given a daily 
total of 150 mg of clomipramine in 3 portions 
at 8:00 AM, 12:00 noon, and 4:00 PM. To es- 
timate the effects of therapy, patients were rated 
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by means of the 21-item ~amiiton scale during 
baseline and on the 19th day of drug treatment. 
Additionally, patients self-rated their mood be- 
fore and after each night in the laboratory along 
the Adjective Mood Scale (AMS) (van Zerssen 
1986). 
Results 
The effects of clomipramine on sleep variables 
in comparison to baseline are shown in Table 
1. With regard to variables of sleep continuity, 
treatment with clomipramine led to a significant 
increase of sleep latency and a decrease of sleep 
efficiency after 19 days of treatment. Parameters 
of sleep architecture were also affected: Stage 
I [percent sleep period time (%SPT)l was sig- 
n~~c~tly enhanced after 19 treatment days. 
whereas Stage 2 was increased only on the first 
treatment day and later returned to baseline lev- 
els. In summary, clomipramine treatment does 
not seem to improve sleep quality but actually 
seems to impair sieep. Regarding REM sleep 
measures, REM latency was signi~cantly 
lengthened during the initial drug night, and 
REM sleep (%SPT) was markedly reduced com- 
pared to baseline. Four patients even showed a 
complete absence of REM sleep during the first 
drug night. On day 19 of clomipramine treat- 
ment. mean REM latency was still 3 times longer 
than during the baseline night; although REM 
sleep suppression was stitl highly significant. 
there was a slight attenuation of REM sleep 
suppression during the treatment period. Onfq 
two patients showed total REM suppression dur- 
ing the 19th night. 
As demonstrated in Table 2, patients signitl 
icantly improved after I9 days of treatment as 
measured by the 2 1 -item Hamilton scale and the 
mean of morning and evening values (AMS). 
As a measure of clinical response, the Hamilton 
value on the 19th day was calculated as per- 
centage of the ~o~esponding value during base- 
line for each patient. Establishing a response 
criterion of at least 30% improvement or mote 
on the 21 -item Hamilton scale, 6 of the 10 pa- 
tients responded well to clomipramine treat,- 
ment. By relating the change in REM sleep 
(%SPTI from baseline night to the first night of 
treatment to this measure of clinical response. 
Table 1. Sleep Parameters in 10 Depressed Patients during Baseline and Treatment with Clomipramine 
(Mean t SD) 
Baseline 
night 
Clomipramine treatment 
Night I Night 19 -_ 
Sleep continuity variables 
Sleep latency (min) 17.6 +- 16.1 29.6 I 30.5 34.1 + 13.4’- 
Early morning awakening (min) 10.9 It 20.8 30.9 i- so.4 39.8 t 4”).1 
Time awake (% SW? 9.2 i. 12.0 6.3 -r 6.0 13.3 t X.1 
Sieep efficiency (% ) x5.4 2 15.5 x1.7 +- 12.5 72.3 + 13.5, 
Sleep architecture 
Stage 1 (%SPT) 8.1 -+ 4.1 9.1 t 6.7 19.5 t X.0 
Stage 2 (%SPT) 50.3 ” 10.8 60.2 It 13.4h 49.6 + 13.0 
Slow-wave sleep f%SPT) 12.2 t 8.0 20.0 i 12.3 10.7 _f x.2 
REM sleep variables 
REM latency (min) 63.7 + 29.7 
REM (%SpT) 19.7 It: 3.6 
“SFT, sleep eriod rime--time from sleep onset till tinal awakening. 
“p < 0.05 in comparison to baseline (Wilcoxon test. two-tailed). 
‘p cl 0.01 m comparison to baseline. 
Brief Reports BIOL PSYCHIATRY 1219 
1986;21:1217-1220 
Table 2. Psycho~~ome~c Measu~ments during 
Baseline and after 19 Days of Ciomipramine 
Treatment in 10 Patients (Mean rt SD) 
Day I9 
Baseline of treatment 
2I-Item Hamilton Score 28.2 r 5.2 16.3 2 9.5b 
AMS (mean of morning 
and evenine values) 39.9 +: 9.4 30.3 2 13.4” 
“p < 0.05 in comparison to baseline (Wilcoxon test, one-tailed). 
“p < 0.01 in comparison to baseline. 
a significant correlation emerged (r = -0.64, 
p < 0.05; Spearman Rank correlation, one-tailed) 
(Figure 1). This means that the higher the REM 
sleep reduction during the first night of treatment 
in comparison to baseline, the better the clinical 
improvement. Concerning patients’ self-rating 
of mood, however, the same correlation did not 
show statistical significance (r = -0.44; 
Spearman Rank correlation, one-tailed). In con- 
trast o Kupfer et al. (1976, 1981) and Gillin et 
al. (1978), changes in REM latency from base- 
line to the first drug night did not correlate with 
clinical improvement. This may be due to the 
fact that REM latency was determinable only 
for six patients during the first drug night, as 
clomip~ine ~eatment led to total REM sleep 
suppression i four subjects. For the same rea- 
son, neither changes in REM density nor first 
REM-episode duration from baseline to first 
treatment night yielded significant correlations 
with therapy response. Considering changes in 
all the other sleep variables (see Table 1) from 
baseline to first treatment night, no significant 
correlations with therapy response could be found. 
Discussion 
By studying the effects of ciomipramine in 10 
depressed patients and monitoring REM sleep 
variables during baseline, initial night of treat- 
Figure 1. Relationship between REM sleep suppression and clinical response in 10 depressed patients (line 
represents regression line). 
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ment, and after f 9 days of treatment, the potent 
REM suppressing efficiency of this drug could 
be demonstrated. Even a dose of 75 mg of clom- 
ipramine led to total REM suppression in 4 of 
the IO patients during the first night of drug 
administration. This is in good agreement with 
Chen f 1979), who claimed that clomipramine is 
the most potent REM-sup~essing tricychc agent. 
The most interesting result of the present study 
is further jllustrated by Figure I. 
As already mentioned. the amount of REM 
sieep suppressed on the initial night of drug 
~eatment in comparison to baseline seems to be 
a good predictor of clinical response. Figure I 
illustrates the relationship between reduction in 
REM sleep and clinical response. For example, 
choosing a cut-off score for REM sleep suppres- 
sion of 15% SPT. onfy one of the seven patients 
showing higher REM sleep reduction did not 
react in the expected way. i.e., did not respond 
to clomipramine treatment although suppressing 
more than 1.5% REM sleep. On the other hand, 
the remaining three patients showing a reduction 
of REM steep of less than 15% SPT are the 
clinically less responsive patients. To further 
validate this finding. and to perhaps establish 
the general cut-off score of REM sleep suppres- 
sion necessary to promote positive clinical re- 
sponse. studies involving larger samples of de- 
pressed patients and using other antidepressant 
drugs should certainfy be conducted. In any case, 
the ~ll~?nito~n~ of REM sleep during antide- 
pressant treatment seems to be a prolnisin~ pre- 
dictor of the efficacy of drug therapy in de- 
pressive disorders. In contrast to Kupfer et al. 
(1981). who administered am~trip~yline~ the ini- 
tial shortening of sleep latency did not predict 
therapy response. This discrepancy might be due 
to different properties of the drugs studied in 
regard to sleep continuity. 
References 
Chen C (1979): Sleep, repression and antideprcs- 
stints. Br J ~~,~~~~j~~~ I35:385-402. 
Gillin JC, Wyatt RJ, Fram D. Snyder F (1978): The 
relationship between changes in REM sleep ahd 
clinical in~provcment i  depressed patients treated 
with amitriptyline. Psvc,hopharmacolog~ 
59:x7-272. 
Kupfer DJ, Foster FG, Reich L, Thompson KS. Weiss 
B (1976): EEG sleep changes as predictors In 
depression. Am .I Psychiatry 133:622-626. 
Kupfer DJ, Spiker DG, Cable P.4, Neil JF, Ulrich 
R, Shaw DH (1981): Sleep and treatment predio- 
tion in endogen(~us depression. Am J Pswhiatr> 
138:429-434. 
Spitzer RL, Endicott JE. Robins E ( 1977): Reseuwh 
Diagnostic Criteria@ a Selected Group qfFunc~- 
tionnl Disorders (3rd ed). New York: New York 
State Psychiatric Institute, Biometric Research. 
Woggon B ( 1983): Prqnrtse &T ~.s~(.~op~~ir~z~~~- 
{)f~zer#pi~. Stuttgart: Enke. 
Zerssen D von (19%): Clinical self-rating sCafe5 
(CSRS) of the Munich Psychiatric lnfo~ation 
System (PSYCHIS ~~n~hen). In Sartorius N, Ban 
‘J teds ). ~.~.~~~~,s~~~~~ f?~ e r .s.~~~)rl. Berf in: Springer. 
pp 270-303. 
